Teva infringed UCB patent, rules Fed Circuit

25-06-2019

Teva infringed UCB patent, rules Fed Circuit

JHVEPhoto / Shutterstock.com

The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro (rotigotine), a patch to treat Parkinson’s disease.


US Court of Appeals for the Federal Circuit, Teva, UCB, Parkinson’s disease, Neupro, Actavis, Watson Laboratories, patent infringement

LSIPR